Ground-breaking new Curtin University-led research has discovered a likely cause of Alzheimer’s disease, in a significant finding that offers potential new prevention and treatment opportunities for Australia’s second-leading cause of death.
The study, published in the prestigious PLOS Biology journal and tested on mouse models, identified that a probable cause of Alzheimer’s disease was the leakage from blood into the brain of fat-carrying particles transporting toxic proteins.
Lead investigator Curtin Health Innovation Research Institute (CHIRI) Director Professor John Mamo said his collaborative group of Australian scientists had identified the probable ‘blood-to-brain pathway’ that can lead to Alzheimer’s disease, the most prevalent form of dementia globally.
“While we previously knew that the hallmark feature of people living with Alzheimer’s disease was the progressive accumulation of toxic protein deposits within the brain called beta-amyloid, researchers did not know where the amyloid originated from, or why it deposited in the brain,” Professor Mamo said.
“Our research shows that these toxic protein deposits that form in the brains of people living with Alzheimer’s disease most likely leak into the brain from fat carrying particles in blood, called lipoproteins.
“This ‘blood-to-brain pathway’ is significant because if we can manage the levels in blood of lipoprotein-amyloid and prevent their leakage into the brain, this opens up potential new treatments to prevent Alzheimer’s disease and slow memory loss.”
Building on previous award-winning research that showed beta-amyloid is made outside the brain with lipoproteins, Professor Mamo’s team tested the ground-breaking ‘blood-to-brain pathway’ by genetically engineering mouse models to produce human amyloid-only liver that make lipoproteins.
“As we predicted, the study found that mouse models producing lipoprotein-amyloid in the liver suffered inflammation in the brain, accelerated brain cell death and memory loss,” Professor Mamo said.
“While further studies are now needed, this finding shows the abundance of these toxic protein deposits in the blood could potentially be addressed through a person’s diet and some drugs that could specifically target lipoprotein amyloid, therefore reducing their risk or slowing the progression of Alzheimer’s disease.”
Alzheimer’s WA Chairman Adjunct Professor Warren Harding said the findings may have a significant global impact for the millions of people living with Alzheimer’s disease.
“Having universities like Curtin working with the pharmaceutical industry is important if we are to tackle this devastating disease,” Mr Harding said.
“In Australia, approximately 250 people are diagnosed with dementia daily, adding to the staggering half a million Australians who are already living with dementia. Without significant medical advances like the breakthrough Professor Mamo’s team has made, it is estimated that the number of Australians living with dementia will exceed one million by 2058. This has a significant impact on families, carers and communities.”
Professor Mamo and his research team’s previous research in this area was awarded the NHMRC-Marshall and Warren Award for the most innovative and potentially transformative research.
Currently, the team is conducting a clinical trial, the Probucol in Alzheimer’s-clinical trial, which is based on previous findings that a historic cardiovascular agent lowers lipoprotein-amyloid production and supports cognitive performance in mice. The mouse models used for this research were developed together with Ozgene.
Original Article: New Curtin research identifies likely cause of Alzheimer’s disease
More from: Curtin University
The Latest on: Alzheimer’s
- MISSING: Jose Arevalo, 83, last seen Friday in Berwyn and suffering from Alzheimer'son December 5, 2022 at 8:49 pm
Arevalo's daughter told us he was last seen sleeping next to his wife – when he got up, walked out the back door, and never came back.
- Blood Test Could Detect Alzheimer’s Years Before Symptoms Occuron December 5, 2022 at 6:49 pm
A simple blood test that can detect Alzheimer’s disease years before symptoms appear may be one step closer to reality, as researchers devise a new method to find it early.
- New Blood Test Can Detect ‘Toxic’ Protein Years Before Alzheimer’s Symptoms Emergeon December 5, 2022 at 4:11 pm
A new blood test can detect toxic amyloid beta oligomers associated with Alzheimer's disease years before symptoms appear.
- Blood test can detect ‘toxic’ protein years before Alzheimer’s symptoms – studyon December 5, 2022 at 2:01 pm
Currently patients tend to receive a diagnosis of Alzheimer’s only after they show well-known signs of the disease.
- Personalized Approach to Alzheimer's Risk Factors Tied to Improved Cognitionon December 5, 2022 at 10:44 am
A personalized intervention that focused on known Alzheimer's risk factors showed "modest" improvement at 2 years that was greater than a control intervention, new results from the SMAART study show.
- Reimagining Alzheimer’s (Part 6): The Many Effects Of The APOE4 Varianton December 5, 2022 at 8:00 am
A novel aspect of the APOE4 genetic predisposition to Alzheimer’s is uncovered and leads to the potential for new diagnostic methods and treatments.
- Lecanemab: Why a new Alzheimer's drug has drawn praise and some concernon December 5, 2022 at 6:00 am
A new contender for the treatment of Alzheimer's disease, lecanemab, may soon be on the market, but what does it really do, and how much promise does it hold, realistically?
- Hopeful glimmers in long war on Alzheimer’s diseaseon December 5, 2022 at 4:56 am
A new study marks the first time a drug altered the underlying biology of Alzheimer's, but there is some debate about the interpretation of the results and their impact.
- Alzheimer's Q&A: More women than men get disease; here are possible reasonson December 5, 2022 at 4:05 am
Studies have found that men and women are equally as likely to develop non-Alzheimer’s dementia as they age, which means there is a particular link between Alzheimer’s disease and gender. Age is the ...
- A new drug appears to slow Alzheimer’s. Here’s what to knowon December 5, 2022 at 4:00 am
An experimental drug appears to slow cognitive decline in people with early onset Alzheimer’s. New data on lecanemab, which is manufactured by Biogen and Esai, was published last week in the New ...
via Bing News
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News